venetoclax + decitabine + azacytidine + cytarabine

This combination therapy is a triple-drug regimen being investigated by Beijing 302 Hospital for the treatment of relapsed/refractory acute myeloid leukemia (AML) or AML with positive minimal residual disease (MRD+). It consists of the BCL-2 inhibitor venetoclax, a hypomethylating agent (either decitabine or azacytidine), and low-dose cytarabine (LDAC). Venetoclax induces apoptosis in leukemia cells by inhibiting the anti-apoptotic protein BCL-2. Hypomethylating agents like decitabine and azacytidine work by inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of tumor suppressor genes. Cytarabine is a pyrimidine analog that interferes with DNA synthesis by inhibiting DNA polymerase. The combination aims to improve response rates in patients who have failed standard therapies.

Other names

Venetoclax + HMA + LDACVenetoclax + Hypomethylating Agent + Low-dose Cytarabine